At the end of June we gathered with the homocystinuria community during the HCU Network America patient and expert conference in Colorado. We were moved to hear from Albert Freedman, Alex Orange Drink, leaders in #newbornscreening, diagnostics, and our very own Sagar Vaidya, VP of clinical development, who gave a talk about our Phase 3 clinical program examining an investigational enzyme replacement therapy for classical HCU. #MovingMountains2024 #InRareForLife
Travere Therapeutics’ Post
More Relevant Posts
-
Learn how biopharma and patient recruitment organizations are overcoming clinical trial recruitment challenges. In this FREE webinar Sara Riordan, MS, CGC, Genome Medical; Bryan Federowicz, xCures; and Jill Pellegrino, AutoCruitment, discuss solutions being implemented now to quickly identify and activate qualified clinical trial patients. Register now ⤵ https://lnkd.in/gRg3gwC4
To view or add a comment, sign in
-
I might have said this before, but I’ll say it again… You don’t want to miss this webinar! Working directly with patients to determine their best treatment options including all acces mechanisms is the future. We all deserve the level of consideration and opportunity that will be detailed in this presentation. Make sure you don’t let this one slip through the cracks. #patientcentric #telehealth #geneticcounseling #healthtech
Learn how biopharma and patient recruitment organizations are overcoming clinical trial recruitment challenges. In this FREE webinar Sara Riordan, MS, CGC, Genome Medical; Bryan Federowicz, xCures; and Jill Pellegrino, AutoCruitment, discuss solutions being implemented now to quickly identify and activate qualified clinical trial patients. Register now ⤵ https://lnkd.in/gRg3gwC4
To view or add a comment, sign in
-
Annovis Bio, Inc. announced that it has completed the final patient study visit in its Phase 3 trial of buntanetap (also known as ANVS401 and Posiphen) for early #ParkinsonsDisease. Buntanetap is unique in that it targets multiple neurotoxic proteins—amyloid β, tau, alpha-synuclein, and TDP43. The once-daily oral treatment is also being studied in Alzheimer’s disease and #DementiaWithLewyBodies. Study results are expected in January 2024. Read more at https://lnkd.in/g7WvTc5s #parkinsonsresearch #parkinsons #alphasynuclein #synucleinopathies https://lnkd.in/eKD2QwR
To view or add a comment, sign in
-
View the role of molecular characteristics in guiding treatment selection and clinical trial enrollment | 0.5-hour CME/CE | Video Activity #2 of 3 in the LGSOC Library #PRIME #CME #MedEd #ovariancancer https://bit.ly/3D7w79Z
To view or add a comment, sign in
-
Join Dr. Young Wang, MD, and Dr. Ingela Mauritzon, PhD, on Wednesday, February 14 at 12:00 PM ET, as they guide you through the intricacies of in vitro diagnostics (IVD). This live webinar addresses the pressing need for standardized regulatory practices in the field of IVDs as advancements are made in an increasingly interconnected global healthcare landscape and demand grows for more precise diagnostics. Enroll today (with or without contact hours) > https://bit.ly/3RV3Sm5 #ACRP #Webinar #ContinuingEducation #InVitroDiagnostics #IVD
To view or add a comment, sign in
-
TOMORROW at 12 PM ET! Don't miss this engaging discussion on the intricacies of in vitro diagnostics with Young Wang, MD, and Ingela Mauritzon, PhD. This live webinar addresses the pressing need for standardized regulatory practices in the field of IVDs as advancements are made in an increasingly interconnected global healthcare landscape and demand grows for more precise diagnostics. Enroll now (with or without contact hours) > https://bit.ly/3RV3Sm5 #ACRP #Webinar #ContinuingEducation #InVitroDiagnostics #IVD
To view or add a comment, sign in
-
Learn how biopharma and patient recruitment organizations are overcoming clinical trial recruitment challenges. In this webinar Sara Riordan MS, CGC, Genome Medical; Bryan Federowicz, xCures; and Jill Pellegrino, AutoCruitment discuss solutions being implemented now to quickly identify and activate qualified clinical trial patients. Register: https://lnkd.in/gRg3gwC4
To view or add a comment, sign in
-
In ERA 2024's best-ranked abstract, we presented 72-week eGFR stabilization from our Phase 2b clinical trial for #IgANephropathy. We also showed rapid hematuria improvement and significantly higher hematuria resolution compared to placebo during the 36-week randomized period. Read the press release here: https://lnkd.in/eRcDMqd5 #ERA24
To view or add a comment, sign in
-
Will you be at #ARVO2024? Let’s connect! Join me for one of the many poster presentations featuring new and updated data demonstrating the potential efficacy of our lead drug candidate for Meibomian Gland Dysfunction (MGD). Session details are in the link below.
✈️ Seattle-bound for #ARVO2024? Learn about the efficacy and safety data from the Phase 2 studies of our lead drug candidate for Meibomian Gland Dysfunction during our 8 poster presentations featuring expert physicians and investigators: https://lnkd.in/g8U_innn #Ophthalmology
To view or add a comment, sign in
-
Intended for HCPs with an interest in GEA: At Jazz, we believe all people, including those who live with complex conditions with limited options, deserve new therapeutic options to help improve outcomes. The HERIZON-GEA-01 clinical trial seeks to explore the safety profile of our investigational treatment for people living with advanced/metastatic human epidermal growth factor receptor 2 (#HER2) positive gastroesophageal adenocarcinomas (#GEAs) and learn if it’s more efficacious than the current standard of care. This trial is currently enrolling eligible patients, learn more: https://lnkd.in/g8RNyyQ8
To view or add a comment, sign in
26,040 followers